KDC-MN-285 – Kodiac biolabs

Plain-language summaryIntrigue 55 / 100

Cetrorelix (Cetrotide) is a GnRH receptor blocker (rather than an agonist), approved in 2000 and used in IVF protocols to prevent the premature LH surge that would otherwise disrupt egg retrieval timing. Unlike GnRH agonists, which cause an initial flare followed by suppression, cetrorelix produces immediate dose-dependent suppression of LH and FSH with no flare. That allows brief, on-demand control of the reproductive axis without the one-to-two-week desensitization delay required of agonists. Standard IVF use is a daily 0.25 mg injection from stimulation day 5 until the trigger shot. Generally well tolerated with minor injection-site reactions. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

42/100

Canonical IVF GnRH antagonist with solid clinical evidence but mature mechanism and eroded class differentiation

Look, cetrorelix is a twenty-five year old approved drug doing exactly what it was designed to do. The GnRH antagonist mechanism here is competitive inhibition at pituitary GnRH receptors: you block the receptor, LH and FSH drop immediately, no flare. That immediate suppression without the 7-to-10-day desensitization period required by GnRH agonists like leuprolide was the whole differentiating story at approval. In 2000 it was genuinely cleaner than anything else in the category. In 2026, the story is thinner.

The evidence base is solid and we wont pretend otherwise. Multiple phase 3 trials underpinned FDA approval, the Cetrotide pivotal data replicated across European and North American centers, and the IVF literature since has been extensive. But this is a narrow clinical corridor. The signal, preventing premature LH surge in controlled ovarian stimulation, is specific enough that it doesnt port easily into other research programs. Off-label use in benign prostatic hyperplasia and prostate cancer leverages the same testosterone-flare-avoidance logic, but in those spaces, degarelix has largely taken over for the extended-suppression indication and relugolix now handles the oral route.

Here’s the thing: the GnRH antagonist class has moved on. Small-molecule oral antagonists, elagolix (endometriosis, uterine fibroids), relugolix (prostate cancer, uterine fibroids), linzagolix, have expanded the pharmacological space considerably. Cetrorelix is a subcutaneous decapeptide competing against pill-form competitors with longer duration, broader approved indications, and more current literature. On differentiation grounds its position has eroded to canonical-reference-only.

What we like: the mechanism is clean, the PK is predictable at roughly 60-hour half-life subcutaneously, and if you’re running HPG axis dynamics in a controlled ovarian stimulation model this is the standard reference tool. The flare-free profile keeps it cleaner than leuprolide for acute suppression study designs.

What we don’t like: single-receptor competitive antagonism, no multi-target angle, no novel biology. The research frontier in GnRH biology has largely shifted upstream to kisspeptin-neurokinin-dynorphin neuron work and the GPR54 axis. Cetrorelix probes the downstream output of the HPG generator, not the generator itself. For investigators trying to understand hypothalamic regulation, thats a real limitation. There’s no significant open question that cetrorelix uniquely answers in 2026. Solid workhorse for reproductive endocrinology labs, genuinely uninteresting to anyone outside that specific program.

Novelty: 22
Mechanism promise: 28
In-category differentiation: 30
Evidence quality: 70
Translational signal: 70
Research bench value: 45

Rationale Cetrorelix scores high on evidence and translational signal because it’s an FDA-approved drug with multiple phase 3 RCTs, but novelty and mechanism promise are low given 25 years of clinical use and straightforward single-receptor competitive antagonism. Differentiation has eroded as oral GnRH antagonists and degarelix have claimed adjacent indications.

Synthetic GnRH antagonist

A synthetic GnRH receptor antagonist used in IVF protocols to prevent premature LH surge; immediate suppression without the agonist flare.

Abstract

Cetrorelix (Ac-D-2-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH2; CAS 120287-85-6; molecular formula C70H92ClN17O14; molecular weight 1431.06) is a synthetic GnRH receptor antagonist decapeptide developed at ASTA Medica and approved by the FDA in 2000 under the trade name Cetrotide. Mechanism: competitive antagonism at pituitary GnRH receptors, producing immediate dose-dependent suppression of LH and FSH without the initial flare characteristic of GnRH agonists. The antagonist mechanism allows brief, on-demand HPG suppression without the 7-to-10-day desensitization period required for GnRH agonist effect. Plasma half-life is approximately 60 hours after subcutaneous dosing. Approved for prevention of premature LH surge in controlled ovarian stimulation for IVF; the daily dose protocol begins on stimulation day 5 and continues through hCG trigger. Off-label use in benign prostatic hyperplasia and prostate cancer (where the avoidance of testosterone flare is clinically valuable). Used as the canonical GnRH antagonist in IVF research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-285Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-285

Cetrorelix

Abstract

Read the full monograph